Genetic testing is carried out to assess the risk of an individual developing a certain disease. Governments across the globe are running awareness campaigns to educate people about the benefits of genetic testing. There is a growing consensus about the benefits of diagnosing diseases, like cancer, in the early stage, through genetic testing. Early diagnosis helps cure the disease or at the least helps contain the impact of the disease.
The North American genetic testing market is expected to register a CAGR of 11.52% during the forecast period of 2018-2023. Due to the screening of genetic mutations with the Cystic Fibrosis Trans-Membrane Conductance Regulator (CFTMR), which is the most recurrently conducted test in the United States, the country occupies the largest share of the market studied.
Increasing Emphasis on Early Disease Detection and Prevention
Many genetic disorders can be detected early in pregnancy, using various invasive and non-invasive techniques. With technological developments, physicians have become capable of performing tests with better accuracy and looking at multiple genes at a time. Consumer demand for safe and effective genetic tests is fueling the growth of this market. Additionally, the growing demand for personalized medicine and increasing application of genetic testing in oncology are also driving the growth of the market studied.
High Costs of Genetic Testing
Cost has always been a barrier to the growth of market studied. A few genetic tests, such as pre-implantation testing (pre-implantation genetic diagnosis or PGD), fecal DNA testing, and others are expensive, and not usually covered by insurance providers. For instance, the BRCA gene evaluation performed by Myriad Genetics, the only company in the United States, is phenomenally expensive, with a price close to USD 4,000, when a related genomic-rearrangement test is included in the analysis, which is typically recommended by oncologists.
Additionally, social and ethical implications of genetic testing and non-inclusion of reimbursement policies are hindering the growth of the market studied.
The United States Expected to Dominate the Market
The North American genetic testing market is segmented by type and geography. By type, the market is segmented into the carrier, diagnostic, newborn, predictive and pre-symptomatic, and prenatal testing. By geography, the market is segmented into the United States, Canada, and Mexico.
Key Developments in the Market
January 2018: Biocartis, a molecular diagnostics company, and Amgen Biotechnology Company entered an agreement for the development of novel oncology compounds.
December 2017: Biocartis, a molecular diagnostics company, and Amgen Biotechnology Company entered an agreement for idylla RAS biomarket tests.
Major Players: 23andMe Inc., Abbott Molecular Inc., Ariosa Diagnostics Inc., Biocartis SA, Cepheid, Illumina Inc., Luminex Corporation, Sequenom Inc., Myriad Genetics, and Transgenomic Inc., amongst others.
Reasons to Purchase This Report
Current and future North American genetic testing market outlook in the developed and emerging markets.
Analyzing various perspectives of the market with the help of Porter’s five forces analysis.
The treatment type that is expected to dominate the market.
Regions that are expected to witness the fastest growth during the forecast period.
Identify the latest developments, market shares, and strategies employed by the major market players.
3 months analyst support along with the Market Estimate sheet (in excel).
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Degree of Competition
6. Market Dynamics
6.1.1 Increasing Emphasis on Early Disease Detection and Prevention
6.1.2 Growing Demand for Personalized Medicine
6.1.3 Increasing Application of Genetic Testing in Oncology
6.2.1 High Cost of Genetic Testing
6.2.2 Social and Ethical Implications of Genetic Testing
7. Market Segmentation
7.1 By Testing Type
7.1.1 Carrier Testing
7.1.2 Diagnostic Testing
7.1.3 Newborn Screening
7.1.4 Predictive and Presymptomatic Testing
7.1.5 Prenatal Testing
7.1.6 Nutrigenomic Testing
7.2 By Disease
7.2.1 Alzheimer’s Disease
7.2.3 Cystic Fibrosis
7.2.4 Sickle Cell Anemia
7.2.5 Duchenne Muscular Dystrophy
7.2.7 Huntington’s Disease
7.2.8 Rare Diseases
7.2.9 Other Diseases
7.3 By Technology
7.3.1 Cytogenetic Testing
7.3.2 Biochemical Testing
7.3.3 Molecular Testing
7.4 By Geography
7.4.1 United states
8. Company Profiles & Competitive Landscape
8.1 Illumina Inc.
8.2 Abbott Molecular Inc.
8.3 23andMe Inc.
8.4 Roche Diagnostics Corp.
8.6 Blueprint Genetic
8.7 Myriad Genetics
8.8 Eurofins Scientific
8.9 Centogene AG
8.10 Thermo Fisher Scientific
** List Not Exhaustive
9. Future of the Market